Core Insights - Foghorn Therapeutics is advancing its clinical programs, particularly FHD-909, a first-in-class oral SMARCA2 selective inhibitor, in a Phase 1 trial targeting SMARCA4-mutated cancers, primarily non-small cell lung cancer (NSCLC) [1][2][3] - The company is developing several selective degrader programs, including Selective CBP, EP300, and ARID1B degraders, with promising preclinical data indicating robust anti-tumor activity and favorable tolerability [2][6][7][8] - Foghorn has a strong financial position with $180.3 million in cash and equivalents as of September 30, 2025, providing a cash runway into 2028 [1][19] FHD-909 Program - FHD-909 is designed to selectively inhibit SMARCA2, showing significant anti-tumor activity in preclinical models of SMARCA4-mutant lung tumors [3][14] - The ongoing Phase 1 trial is progressing well, with enrollment on track and preclinical data supporting its combination with standard therapies [4][2] Selective Degrader Programs - The Selective CBP degrader is entering non-GLP toxicology studies with potential applications in EP300-mutant cancers and ER+ breast cancer, aiming for IND readiness in 2026 [1][12] - The Selective EP300 degrader is showing broad efficacy across hematological malignancies, with IND-enabling studies expected in 2026 [1][7][12] - The Selective ARID1B degrader is advancing towards in vivo proof of concept in 2026, targeting ARID1A-mutated cancers, which represent up to 5% of solid tumors [1][8][13] Financial Performance - Collaboration revenue increased to $8.2 million for Q3 2025, up from $7.8 million in Q3 2024, driven by advancements in programs under the Lilly collaboration [19] - Research and development expenses decreased to $20.0 million in Q3 2025 from $24.7 million in Q3 2024, attributed to reduced costs in various areas [19] - The net loss for Q3 2025 was $15.8 million, an improvement from a net loss of $19.1 million in the same quarter of the previous year [19][22] Leadership Update - The Chief Financial Officer, Kristian Humer, will be leaving the company, with a search for a successor already underway [10]

Core Viewpoint - The conference call focuses on Foghorn's proprietary programs, particularly the selective ARID1B degrader, along with updates on other programs like selective CBP and EP300 degraders [2][4]. Group 1: Company Overview - Karin Hellsvik, Vice President of Investor Relations and Corporate Affairs, leads the call and emphasizes the focus on Foghorn's selective ARID1B degrader and other proprietary programs [2]. - Adrian Gottschalk, President and CEO, will provide an overview of the company's recent progress [4]. Group 2: Pipeline Updates - The call will include updates on the progress of Foghorn's proprietary pipeline programs, specifically ARID1B, CBP, and EP300, along with new data presented [4].

Foghorn Therapeutics FY Conference Call Summary Company Overview - **Company**: Foghorn Therapeutics (NasdaqGM:FHTX) - **Date of Call**: October 30, 2025 - **Focus**: Updates on proprietary programs including selective ARID1B, CBP, and EP300 degraders [1][2][3] Key Industry Insights - **Chromatin Regulatory System**: Foghorn Therapeutics targets the chromatin regulatory system, which is implicated in cancer, with mutations found in up to 50% of tumors [4][5] - **Market Opportunity**: Successful drugs targeting this biology represent multi-billion-dollar opportunities [5] Core Programs and Developments 1. **FHD-909** - **Description**: First-in-class selective oral small molecule inhibitor of SMARCA2, targeting tumors with SMARCA4 mutations [7] - **Clinical Trial**: Currently enrolling patients in a phase 1 dose escalation trial in the US and Japan, focusing on non-small cell lung cancer patients with SMARCA4 mutations [8] - **Timeline**: Anticipated decision on dose expansion by Lilly in the first half of 2026 [8] 2. **Selective ARID1B Degrader** - **Significance**: First to publicly demonstrate robust degradation of ARID1B, targeting a population with ARID1A mutations found in approximately 5% of solid tumors [9][10] - **Clinical Context**: ARID1A mutations accelerate tumor genesis and promote metastases, indicating a high unmet medical need [17] - **Progress**: Achieved 80% degradation in preclinical models, with in vivo proof of concept expected in 2026 [19][20] 3. **Selective CBP Degrader** - **Target Population**: Potential in EP300 mutated cancers and ER-positive breast cancer, with over 200,000 cases diagnosed annually in the US [24][25] - **Mechanism**: Selective degradation of CBP could provide a wider therapeutic window than dual CBP/EP300 inhibitors, avoiding hematological toxicities [24][27] - **Development Status**: Pre-development candidate CBP degrader (CPPD171) is on track for IND readiness in 2026 [10][28] 4. **Selective EP300 Degrader** - **Target Indications**: Significant potential in hematological malignancies, particularly multiple myeloma, with approximately 100,000 patients in the US potentially benefiting [31][32] - **Clinical Validation**: Previous dual CBP/EP300 inhibitors have shown compelling results in multiple myeloma, supporting the approach [34] - **Development Timeline**: Tracking towards IND-enabling studies in 2026 [38] Additional Insights - **Mechanistic Understanding**: Foghorn emphasizes a biology-first approach, focusing on novel biology and targets, with a deep mechanistic understanding of the chromatin regulatory system [5][6] - **Partnership Strategy**: The company is considering partnerships for larger tumor types, particularly in breast cancer and multiple myeloma, to leverage resources for clinical studies [80][81] - **Feedback from Conferences**: Positive feedback received on the selective degradation of ARID1B, indicating significant interest and curiosity from industry peers [83] Conclusion Foghorn Therapeutics is advancing a robust pipeline of selective degraders targeting critical components of the chromatin regulatory system, with significant potential to address unmet medical needs in various cancers. The company is on track for key milestones in 2026, including IND readiness for multiple programs.

Core Insights - Foghorn Therapeutics Inc. is advancing its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs, showcasing significant progress in addressing challenging cancer targets [1][2] Selective ARID1B Degrader Program - The Selective ARID1B degrader targets a dependency found in up to 5% of solid tumors, including endometrial, gastric, gastroesophageal junction, bladder, and non-small cell lung cancer [3][5] - The program is advancing towards in vivo proof of concept expected in 2026, with recent data presented at the TPD and Induced Proximity Summit [4][5] Selective CBP Degrader Program - The Selective CBP degrader is on track for non-GLP toxicology studies in Q4 2025, with potential applications in EP300-mutant cancers and ER+ breast cancer, aiming for IND readiness in 2026 [5][8] - The program is designed to overcome challenges associated with dual inhibition of CBP and EP300, which have shown dose-limiting toxicities [7][9] Selective EP300 Degrader Program - The Selective EP300 degrader is focused on hematological malignancies such as multiple myeloma and diffuse large b-cell lymphoma, with IND-enabling studies planned for 2026 [9][10] - This program demonstrates encouraging anti-tumor efficacy and favorable tolerability in preclinical studies, differentiating itself from dual CBP/EP300 approaches [5][10] Company Overview - Foghorn Therapeutics is developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system, utilizing its Gene Traffic Control platform [11]

Core Insights - Foghorn Therapeutics is hosting a virtual investor event on October 30, 2025, to discuss updates on its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs [1][3] - The company will present significant progress on its Selective ARID1B degrader program at the TPD and Induced Proximity Summit, highlighting its potential for treating endometrial, gastric, and bladder cancers [2] Company Overview - Foghorn Therapeutics is focused on discovering and developing a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system [4] - The company utilizes its proprietary Gene Traffic Control platform to systematically study and validate potential drug targets within this system, with multiple product candidates in oncology [4] Event Details - The Keynote Plenary session will feature a presentation titled "Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins" on October 29, 2025 [3] - The virtual investor event will provide pipeline updates and will be accessible via the company's website after the conference [3]

Core Insights - Foghorn Therapeutics is advancing its pipeline, particularly focusing on FHD-909, a first-in-class oral SMARCA2 selective inhibitor, which is currently in a Phase 1 dose escalation trial targeting non-small cell lung cancer (NSCLC) [1][3][4] - The company has shown promising preclinical data indicating synergistic effects of FHD-909 when combined with pembrolizumab and KRAS inhibitors, suggesting significant potential in treating difficult-to-treat NSCLC [2][4] - Foghorn's selective degrader programs targeting CBP, EP300, and ARID1B are progressing well, with updates expected in Q4 2025 and an IND application for the Selective CBP degrader anticipated in 2026 [2][6][12] Financial Overview - As of June 30, 2025, Foghorn reported cash, cash equivalents, and marketable securities totaling $198.7 million, providing a cash runway into 2028 [1][18] - Collaboration revenue for the three months ended June 30, 2025, was $7.6 million, an increase from $6.9 million in the same period in 2024, driven by advancements in programs under the Lilly Collaboration Agreement [10][21] - The net loss for the three months ended June 30, 2025, was $17.9 million, compared to a net loss of $23.0 million for the same period in 2024, indicating improved financial performance [18][21] Pipeline and Development Programs - FHD-909 is designed to selectively inhibit SMARCA2, which is crucial for the survival of tumors with SMARCA4 mutations, and has shown significant anti-tumor activity in preclinical models [3][13] - The Selective CBP degrader program targets EP300-mutated cancer cells and has shown encouraging activity in ER+ breast cancer, with potential applications beyond EP300-mutant tumors [2][6][11] - The Selective EP300 degrader is being developed for hematological malignancies and prostate cancer, with updates expected in Q4 2025 [7][11] - The Selective ARID1B degrader targets ARID1B in ARID1A-mutated cancers, which are prevalent in various solid tumors, and has achieved selective degradation in preclinical studies [8][12] Strategic Collaborations - Foghorn is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for FHD-909, which is currently enrolling patients in a Phase 1 trial [4][5] - The collaboration aims to develop novel oncology medicines, leveraging both companies' strengths in drug development [4][5]

Core Insights - Foghorn Therapeutics is advancing its FHD-909 (LY4050784) in a Phase 1 dose escalation trial targeting SMARCA4 (BRG1) mutated cancers, primarily focusing on non-small cell lung cancer (NSCLC) [1][11] - The company presented data at the AACR Annual Meeting showing synergistic effects of FHD-909 in combination with pembrolizumab and KRAS inhibitors, supporting further clinical exploration [1][11] - Foghorn has a strong financial position with $220.6 million in cash and equivalents as of March 31, 2025, providing a cash runway into 2027 [1][19] Pipeline Progress - FHD-909 is a first-in-class oral SMARCA2 selective inhibitor, demonstrating high selectivity over SMARCA4, with potential applications in various cancers [7][16] - The Selective CBP degrader program is showing promise in ER+ breast cancer, with preclinical data indicating combinatorial benefits with existing therapies [12][9] - The Selective EP300 degrader program is advancing, showing anti-proliferative activity in hematological malignancies, with updates expected in H2 2025 [10][18] Corporate Developments - Foghorn appointed Neil Gallagher, M.D., Ph.D., and Stuart Duty to its Board of Directors, enhancing its leadership team with extensive experience in drug development and finance [4] - The company hosted its second annual Chromatin Regulation Summit, focusing on targeted protein degradation and induced proximity, featuring industry experts [5][6] Financial Performance - Collaboration revenue increased to $6.0 million for Q1 2025, up from $5.1 million in Q1 2024, driven by advancements in programs under the Lilly collaboration [19] - Research and development expenses decreased to $21.6 million in Q1 2025 from $25.5 million in Q1 2024, attributed to reduced costs in various areas [19] - The net loss for Q1 2025 was $18.8 million, an improvement from a net loss of $25.0 million in Q1 2024 [19][22]

Core Insights - Foghorn Therapeutics Inc. is advancing its clinical-stage pipeline, particularly focusing on FHD-909, a selective SMARCA2 inhibitor, which is currently in Phase 1 trials targeting SMARCA4 mutated cancers, primarily non-small cell lung cancer (NSCLC) [1][2][5] Group 1: FHD-909 Program - FHD-909 demonstrates synergistic anti-tumor activity when combined with chemotherapy, KRAS inhibitors, and pembrolizumab, warranting further clinical exploration [1][4] - The ongoing Phase 1 trial of FHD-909 is evaluating patients with SMARCA4 mutations who have exhausted standard treatment options, with a focus on NSCLC and other advanced solid tumors [5][9] - Preclinical studies indicate that FHD-909 selectively inhibits SMARCA4 mutant cancer cells and shows robust anti-tumor efficacy in xenograft models [4][13] Group 2: Selective CBP and EP300 Degrader Programs - The Selective CBP degrader program shows promise in preclinical models, indicating potential benefits in solid tumors beyond EP300-mutant cancers [6][10] - Initial preclinical data for the Selective EP300 degrader program suggests significant anti-cancer activity in hematological malignancies, with ongoing characterization of its therapeutic potential [7][11] - The Selective ARID1B degrader program is also in development, targeting a synthetic lethal mechanism implicated in up to 5% of all solid tumors [8][16] Group 3: Upcoming Events and Presentations - Foghorn management will hold a virtual investor event on April 29, 2025, to discuss pipeline updates, including the FHD-909 program and other ongoing research efforts [2][12] - A poster presentation on the Selective EP300 degrader program is scheduled for April 30, 2025, at the AACR Annual Meeting [2][7]

Core Insights - Foghorn Therapeutics is set to present new preclinical combination data for FHD-909, a potential first-in-class selective SMARCA2 inhibitor targeting non-small cell lung cancer (NSCLC) [1][2] - The company will also share updates on its Selective CBP and EP300 degrader programs, along with an overview of the Selective ARID1B degrader program during a virtual investor event on April 29, 2025 [1][2][3] Company Overview - FHD-909 (LY4050784) is an allosteric, orally available small molecule that selectively inhibits the ATPase activity of SMARCA2, showing significant anti-tumor activity in preclinical studies involving SMARCA4 mutant lung tumor models [4] - Foghorn Therapeutics focuses on developing a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system, utilizing its Gene Traffic Control platform to identify and validate drug targets [5]